Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025
Globenewswire·2025-07-31 05:00
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 We also wish to thank Els Vandecandelaere, who will be stepping down from the Board. Her guidance and commitment have been instrumental in Fagron's development into a leader in personalized medicine. Looking ahead, we remain confident in our outlook and are reiterating both our FY 2025 and mid- ...